Dose‐Dependent Effects of Betaxolol in Hypertension: A Double‐Blind, Multicenter Study

Williams, Roger L.; Goyle, Krishan K.; Herman, Theodore S.; Rofman, B A; Ruoff, Gary; Hogan, Leo B.

doi:10.1002/j.1552-4604.1992.tb03848.x

Cited by 3 publications

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study demonstrates the possibility to use this drug in patients with heart failure. However, the main indication for betaxolol treatment is hypertension [7,8].…”

Section: Introductionmentioning

confidence: 99%

Association of CYP2D6 and ADRB1 genes with hypotensive and antichronotropic action of betaxolol in patients with arterial hypertension

Zateyshchikov

Brovkin

et al. 2007

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

Betaxolol is a selective antagonist of beta(1)-adrenergic receptors. Personal response to the drug widely varies and depends on its properties and individual features including innate characteristics. Our aim was to study the association between the clinical response to betaxolol in patients with essential hypertension (EH) and polymorphous markers of two genes: beta(1) adrenergic receptor gene (ADRB1) and cytochrome P450 2D6 gene (CYP2D6). Eighty-one patients with EH were selected. Mean age was 52.2 +/- 1.22 years. Betaxolol monotherapy provided effective blood pressure control (BP < 140/90 mmHg) in 68 patients, 56 of them continued treatment with initial dose. The systolic (SBP) and diastolic (DBP) blood pressure declined significantly at the end of the study. We have not found any significant association of rest and exercise BP and heart rate (HR) with polymorphous marker Arg389Gly of ADRB1 gene except the nighttime variability of DBP. But in case of the polymorphous marker Pro34Ser of CYP2D6 gene we have found significant association with response to betaxolol therapy. The rest HR declined more significantly in Ser/Pro genotype carriers (-32.6 +/- 4.77 beats/min and -18.4 +/- 2.01 beats/min, P = 0.023). These patients demonstrated more significant increase of exercise time (4.58 +/- 0.90 and 0.59 +/- 0.58 min, P = 0.045). Maximal exercise HR and DBP were also significantly lower in Ser/Pro genotype carriers in comparison with Ser/Ser genotype carriers. Decline of mean daytime SBP in 24-h ambulatory blood pressure monitoring was more significant in Pro allele carriers (-21.0 +/- 2.55 mmHg vs. -5.2 +/- 2.27 mmHg in patients with Ser/Ser genotype, P = 0.001). Betaxolol effect on HR and BP significantly depends on variability of the gene determining the drug metabolism. The carriers of Pro34 allele of CYP2D6 gene (8.6%) are more sensitive to betaxolol therapy. Because of the relatively small group sizes our data should be considered as preliminary ones. The increase of our groups and the replication in other studies will permit to estimate the contribution of genetic factors to betaxolol effect on HR and BP.

show abstract

“…This study demonstrates the possibility to use this drug in patients with heart failure. However, the main indication for betaxolol treatment is hypertension [7,8].…”

Section: Introductionmentioning

confidence: 99%

Association of CYP2D6 and ADRB1 genes with hypotensive and antichronotropic action of betaxolol in patients with arterial hypertension

Zateyshchikov

Brovkin

et al. 2007

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

show abstract

Blood pressure lowering efficacy of beta-1 selective beta blockers for primary hypertension

Wong

Boyda

Wright

2016

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

This review provides low quality evidence that in people with mild to moderate hypertension, beta-1 selective blockers lowered BP by an average of -10/-8 mmHg and reduced heart rate by 11 beats per minute as compared to placebo. The effect of beta-1 blockers at peak hours, -12/-9 mmHg, was greater than the reduction at trough hours, -8/-7 mmHg. Beta-1 selective blockers lowered BP by a greater magnitude than dual receptor beta-blockers and partial agonist beta-blockers, lowered BP similarly to nonselective beta-blockers. Beta-1 selective blockers lowered SBP by a similar degree and lowered DBP by a greater degree than diuretics, angiotensin converting enzyme inhibitors and angiotensin receptor blockers. Because DBP is lowered by a similar extent to SBP, beta-1 selective blockers do not reduce pulse pressure.

show abstract

Effect of betaxolol hydrochloride on heart rate variability indices during exercise stress testing in patients with hypertension

Takase

Abe

Nagata

et al. 2005

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

Dose‐Dependent Effects of Betaxolol in Hypertension: A Double‐Blind, Multicenter Study

Cited by 3 publications

References 13 publications

Association of CYP2D6 and ADRB1 genes with hypotensive and antichronotropic action of betaxolol in patients with arterial hypertension

Association of CYP2D6 and ADRB1 genes with hypotensive and antichronotropic action of betaxolol in patients with arterial hypertension

Blood pressure lowering efficacy of beta-1 selective beta blockers for primary hypertension

Effect of betaxolol hydrochloride on heart rate variability indices during exercise stress testing in patients with hypertension

Contact Info

Product

Resources

About